TransCode Therapeutics Statistics

Total Valuation

RNAZ has a market cap or net worth of $1.34 million. The enterprise value is -$386,583.

Market Cap	1.34M
Enterprise Value	-386,583

Important Dates

The next estimated earnings date is Monday, March 31, 2025, after market close.

Earnings Date	Mar 31, 2025
Ex-Dividend Date	n/a

Share Statistics

RNAZ has 696,249 shares outstanding.

Current Share Class	696,249
Shares Outstanding	696,249
Shares Change (YoY)	n/a
Shares Change (QoQ)	+108.27%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	11.88%
Float	582,722

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.61
P/TBV Ratio	0.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.09.

Current Ratio	1.58
Quick Ratio	0.82
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-346.50

Financial Efficiency

Return on equity (ROE) is -490.03% and return on invested capital (ROIC) is -268.05%.

Return on Equity (ROE)	-490.03%
Return on Assets (ROA)	-129.43%
Return on Invested Capital (ROIC)	-268.05%
Return on Capital Employed (ROCE)	-887.68%
Revenue Per Employee	n/a
Profits Per Employee	-$1.49M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -91.92% in the last 52 weeks. The beta is 1.15, so RNAZ's price volatility has been higher than the market average.

Beta (5Y)	1.15
52-Week Price Change	-91.92%
50-Day Moving Average	5.89
200-Day Moving Average	16.63
Relative Strength Index (RSI)	29.68
Average Volume (20 Days)	1,898,769

Short Selling Information

The latest short interest is 162,852, so 23.39% of the outstanding shares have been sold short.

Short Interest	162,852
Short Previous Month	368,311
Short % of Shares Out	23.39%
Short % of Float	27.95%
Short Ratio (days to cover)	0.04

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-14.67M
Pretax Income	-17.06M
Net Income	-14.93M
EBITDA	-14.55M
EBIT	-14.67M
Earnings Per Share (EPS)	-$71.81

Full Income Statement

Balance Sheet

The company has $1.88 million in cash and $152,481 in debt, giving a net cash position of $1.72 million or $2.48 per share.

Cash & Cash Equivalents	1.88M
Total Debt	152,481
Net Cash	1.72M
Net Cash Per Share	$2.48
Equity (Book Value)	1.65M
Book Value Per Share	3.16
Working Capital	1.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$15.85 million and capital expenditures -$21,261, giving a free cash flow of -$15.87 million.

Operating Cash Flow	-15.85M
Capital Expenditures	-21,261
Free Cash Flow	-15.87M
FCF Per Share	-$22.80

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-1,116.59%
FCF Yield	-1,187.49%

Analyst Forecast

The average price target for RNAZ is $20.00, which is 941.67% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.00
Price Target Difference	941.67%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on December 4, 2024. It was a reverse split with a ratio of 0.030303:1.

Last Split Date	Dec 4, 2024
Split Type	Reverse
Split Ratio	0.030303:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a